Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP

Lepore, Domenico; Ji, Marco H.; Quinn, Graham E.; Amorelli, Giulia Maria; Orazi, Lorenzo; Ricci, Daniela

doi:10.3928/23258160-20200228-07

Cited by 10 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It suggested that immature development of inner retinal layers and delayed development of the ellipsoid zone at the foveal center might have been induced by laser photocoagulation in ROP patients. Lepore et al have compared 36 eyes of 18 patients with one eye treated with laser photocoagulation and the other eye treated with intravitreal bevacizumab injection for type 1 ROP 24 . Eyes treated with intravitreal bevacizumab tended to have thinner foveal thickness than eyes treated with laser photocoagulation.…”

Section: Discussionmentioning

confidence: 99%

Retinal and peripapillary vascular deformations in prematurely born children aged 4–12 years with a history of retinopathy of prematurity

Lee

Park

et al. 2023

Sci Rep

View full text Add to dashboard Cite

In this study, foveal, parafoveal, peripapillary anatomical, and microvascular anomalies in prematurely born children aged 4–12 years with a history of retinopathy of prematurity (ROP) were evaluated. Seventy-eight eyes of 78 prematurely born children ([tROP]: ROP with laser treatment, [srROP]: spontaneously regressed ROP) and 43 eyes of 43 healthy children were included. Foveal and peripapillary morphological parameters (including ganglion cell and inner plexiform layer (GCIPL) thickness, peripapillary retinal nerve fiber layer (pRNFL) thickness) and vasculature parameters (including foveal avascular zone area, vessel density from superficial retinal capillary plexus (SRCP), deep retinal capillary plexus (DRCP), and radial peripapillary capillary (RPC) segments) were analyzed. Foveal vessel densities in SRCP and DRCP were increased and parafoveal vessel densities in SRCP and RPC segments vessel density were decreased in both ROP groups compared with those of control eyes. The best-corrected visual acuity was negatively correlated with pRNFL thickness in the tROP group. Refractive error was negatively correlated with vessel density of RPC segments in the srROP group. In children born preterm with a history of ROP, it was found that foveal, parafoveal, and peripapillary structural and vascular anomalies and redistribution were accompanied. These retinal vascular and anatomical structure anomalies showed close relationships with visual functions.

show abstract

Section: Discussionmentioning

confidence: 99%

Retinal and peripapillary vascular deformations in prematurely born children aged 4–12 years with a history of retinopathy of prematurity

Lee

Park

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, in posterior zone-affected severe ROP patients, this treatment results in low efficacy and high ocular complications. 9 13 14 15 In recent years, anti-VEGF agents are considered an attractive therapeutic strategy because of their key role in the pathophysiology of disease and advantages over ablative therapy, especially in Zone 1. 16 …”

Section: Discussionmentioning

confidence: 99%

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone Ii

Milani

Bagheri

Niyousha

et al. 2022

Journal of Current Ophthalmology

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of intravitreal injection (IVI) of bevacizumab (IVB) versus aflibercept (IVA) in premature infants with type 1 prethreshold retinopathy of prematurity (ROP) in the posterior Zone II. Methods: The study was a multicenter, historical cohort of premature newborns diagnosed with type 1 prethreshold ROP in the posterior Zone II, treated with IVB or IVA. Demographic features, complications, and treatment outcomes were then compared between the two groups. Results: Seventy-six patients received aflibercept (the IVA group), and 210 received bevacizumab (the IVB group). The two groups were not significantly different in terms of postmenstrual age (PMA) at the time of ROP diagnosis and other known risk factors for ROP development and progression. All eyes in both the groups responded to IVI; however, recurrence was observed in four eyes (1.9%) in the IVB group and 12 (15.8%) in the IVA group (P = 0.001). Recurrence occurred 9.1 ± 0.83 (5–12) and 15.5 ± 0.98 (12–18) weeks after primary treatment in the IVB and IVA groups, respectively (P = 0.000). In the IVA group, retinal vascularization was completed in 38.18 ± 6.5 weeks (21–48) after IVI, and it happened in 23.86 ± 9.3 weeks (13–60) in the IVB group (P = 0.009). Furthermore, vascularization reached the peripheral retina in 73.25 ± 6.5 (56–84) and 58.75 ± 8.8 (45–93) weeks, PMA in the IVA and IVB groups, respectively (P = 0.03). No acute postoperative complications were observed in the treated eyes in either group. Conclusion: This study shows that both IVA and IVB are effective and well tolerated for the management of type 1 prethreshold ROP in the posterior Zone II; however, IVA needs a significantly longer time for vascularization completion and has a higher recurrence rate compared with IVB.

show abstract

“…The persistent avascular retina can stimulate reactivation or recurrence of the vasoproliferation, as evidenced in studies of preterm infant eyes treated with bevacizumab for severe ROP. 7 …”

Section: Introductionmentioning

confidence: 99%

Avascular Peripheral Retina in Infants

Özdek¹,

Zeydanlı²,

Baumal³

et al. 2023

tjo

View full text Add to dashboard Cite

Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP

Cited by 10 publications

References 33 publications

Retinal and peripapillary vascular deformations in prematurely born children aged 4–12 years with a history of retinopathy of prematurity

Retinal and peripapillary vascular deformations in prematurely born children aged 4–12 years with a history of retinopathy of prematurity

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone Ii

Avascular Peripheral Retina in Infants

Contact Info

Product

Resources

About